APSR2026-369

Yes
Late-Breaking
Submitted
Oral Presentation
AO19-005
 
 
https://storage.unitedwebnetwork.com/files/1285/1213547-46903-APSR26 AO19-005 Rong Lih Ho_440582.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
7

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

RONG LIH HO * Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
HEMA YAMINI RAMARMUTY - Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
SENG WEE CHEO - Sabah Women and Children Hospital 2Department of Oncology Kota Kinabalu Malaysia
WAN YI LEONG - Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
SUNN-REN TEE - Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
PRISAANA RAMAKRISHNAN - Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
KUNJI KANNAN SIVARAMAN KANNAN - Queen Elizabeth Hospital Department of Respiratory Medicine Kota Kinabalu Malaysia
 
 
 
 
 
 
 
 
Presenting Author Details
RONG LIH
HO
ronglih12@gmail.com
+60109313390
31-40
Malaysia
Original Research
Clinical and Genomic Characteristics of Lung Adenocarcinoma with Malignant Central Airway Obstruction
Maximum 25 words
Abstract Content
Background: Malignant central airway obstruction (MCAO) occurs in 20–30% of primary lung cancers. Lung adenocarcinoma in Asian populations commonly harbours epidermal growth factor receptor (EGFR) mutations (40–50%), which are associated with improved survival. The pattern of genomic mutations in adenocarcinoma presenting with MCAO remains unclear. Objective: To determine the prevalence of actionable genomic alterations (AGA), including EGFR mutations, and associated survival outcomes in lung adenocarcinoma patients with MCAO.
Methods: A retrospective review of 21 patients with MCAO who underwent rigid bronchoscopy (RB) between February 2025 and January 2026 was performed. Lung adenocarcinoma cases underwent either single-gene EGFR/ALK testing or next-generation sequencing (NGS). Clinical characteristics, interventions, and mortality were analysed.
Results: Of 21 MCAO cases, 9 (47%) had adenocarcinoma. The median age was 63 years, and 63.6% were male. Among adenocarcinoma cases, five underwent NGS and four had single-gene EGFR/ALK testing. One patient (11%) had an EGFR exon 19 deletion; three others had BRAF V600E mutation, MET fusion, and KRAS G12C mutation, respectively. Five patients (56%) had no identifiable AGA. The 3-month mortality was 33%, with three deaths occurring within one month. Mortality was numerically higher in patients without AGA (60% vs 25%, p=0.52) and in those requiring airway stenting (60% vs 25%, p=0.52); however, these differences were not statistically significant. Higher mortality observed in the airway stenting group is likely attributable to greater disease severity and more complex airway involvement, rather than stent-related complications.
Conclusion: In this cohort, lung adenocarcinoma presenting with MCAO was associated with a low EGFR mutation rate and substantial early mortality. Interpretation is limited by small sample size and heterogeneous genomic testing, as not all patients underwent NGS. Larger studies are required to validate these findings.
 
 
 
 
 
No
No
https://storage.unitedwebnetwork.com/files/1285/1213547-37089-Tables_379224.jpg
JPG or JPEG or PNG format ONLY
Genomic characteristics, Lung adenocarcinoma, Malignant central airway obstruction
maximum 3 keywords and no abbreviations, separated by commas
-
289